和脂质的超分子共聚物及其治疗潜力
Ruomeng Qiu1, Ivan R Sasselli1,2, Zaida Álvarez2,3
1Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208, United States.
Journal of the American Chemical Society
|March 17, 2022
概括
研究人员使用自组合开发了新型的超分子共聚物. 在阿尔茨海默病模型中,这些生物材料显示出可控药物输送的潜力,增强神经元细胞活力.
科学领域:
- 超分子化学
- 的自组装
- 生物材料科学
背景情况:
- 超分子化学可以创造先进的生物材料.
- 是治疗系统的有希望的候选者.
- 控制组合是设计功能材料的关键.
研究的目的:
- 研究脂质和可溶性的联合组合.
- 创建具有可调整内部结构的超分子共聚物.
- 探索这些共聚物的药物输送和治疗应用的潜力.
主要方法:
- 脂质β片形成与可溶性的联合组合.
- 在不同度下对高分子共聚物结构的表征.
- 对释机制和热力学转移稳定性的评估.
- 使用阿尔茨海默病候选药物进行体外测试.
主要成果:
- 联合组装产生了具有不同内部顺序的超分子共聚物.
- 在低度下,可溶性在水中受到保护.
- 在较高的度下,共聚化破坏了β片的二次结构.
- 热力学转基因稳定性促进了自发单体释放.
结论:
- 超分子共聚物为生物材料设计提供了多功能平台.
- 从这些组合中控制释放是一种可行的药物递送机制.
- 这些系统在阿尔茨海默病背景下显示了神经元细胞活力的增强.
相关概念视频
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.6K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.6K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.4K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.4K
Drugs for Treatment of Constipation-Predominant IBS
1.5K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.5K
Peptic Ulcer Disease IV: Management
815
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
815
Chronic Pancreatitis II: Collaborative Care
572
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
572
Chronic Pancreatitis II: Pathophysiology
35
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
35


